HeartSciences

Executive Summary

HeartSciences is a U.S.-based medical technology company pioneering the application of artificial intelligence to the standard electrocardiogram (ECG). Founded in 2001, the company develops AI-ECG solutions designed to enhance the early detection of cardiovascular conditions, including those often missed by conventional ECG analysis. By leveraging a non-invasive, ubiquitous test, HeartSciences aims to improve diagnostic accuracy and expand clinical utility in primary care and cardiology settings. The company has achieved an "Approved" stage, suggesting regulatory clearance for its core platform, positioning it for commercialization. The market opportunity for AI-enhanced ECG diagnostics is substantial, driven by the prevalence of heart disease and the need for cost-effective screening tools. HeartSciences' technology could address significant unmet needs in early detection of conditions like atrial fibrillation, heart failure, and myocardial ischemia. With regulatory approval in hand, the company's near-term focus is likely on commercial launch, clinical adoption, and strategic partnerships. Key catalysts include securing reimbursement, generating real-world evidence, and expanding into international markets. If successful, HeartSciences could capture a meaningful share of the global cardiac diagnostics market.

Upcoming Catalysts (preview)

• Q2 2026FDA clearance for AI-ECG detection of left ventricular dysfunction80% success
• Q3 2026Strategic partnership with a major hospital network for clinical deployment60% success
• Q3 2026Publication of pivotal clinical trial results in peer-reviewed journal70% success